Bezin et al.’s study [52] on the risk of thyroid cancer associated with GLP-1 receptor agonists diverges from our findings regarding semaglutide, suggesting a potential increased risk for thyroid cancer. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.